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http://dx.doi.org/10.1016/j.ccell.2014.10.019SUMMARYSmall cell lung cancer (SCLC) is an aggressive disease with high mortality, and the identification of effective
pharmacological strategies to target SCLC biology represents an urgent need. Using a high-throughput
cellular screen of a diverse chemical library, we observe that SCLC is sensitive to transcription-targeting
drugs, in particular to THZ1, a recently identified covalent inhibitor of cyclin-dependent kinase 7. We find
that expression of super-enhancer-associated transcription factor genes, includingMYC family proto-onco-
genes and neuroendocrine lineage-specific factors, is highly vulnerability to THZ1 treatment. We propose
that downregulation of these transcription factors contributes, in part, to SCLC sensitivity to transcriptional
inhibitors and that THZ1 represents a prototype drug for tailored SCLC therapy.INTRODUCTION
Lungcancer accounts for nearly 30%of all cancer-relateddeaths.
In 10% to 15%of lung cancer cases, patients are diagnosed with
small cell lung cancer (SCLC), themostmalignant subtype of lung
cancer, characterizedbyaggressivegrowth,earlyonsetofmetas-
tasis, and rapid development of chemorefractory disease. The 5
year survival rate for SCLC patients is less than 5%, a poor prog-
nosis that has not changed in four decades, because of the lack ofSignificance
In contrast to other lung carcinomas, there has been no signific
introduction of chemotherapy in the 1970s. Although SCLC tu
genomic characterization of SCLC has thus far not revealed dru
transcription apparatus, including a covalent inhibitor of CDK7
ber of THZ1-responsive transcripts, including super-enhancer
tion factors, whose vulnerability to THZ1 contributes to SCLC s
these candidate SCLC proto-oncogenes, leading to a viable th
Caadvances in SCLC therapeutics (Sato et al., 2007; William and
Glisson, 2011). In contrast to non-small cell lung cancer (NSCLC),
for which therapeutics designed to target known oncogenic
drivers such as EGFR and ALK have been extremely effective,
the poor understanding of SCLC disease etiology has precluded
the identification of therapeutic targets and effective treatments
(William and Glisson, 2011). Recent efforts to collect and
sequence SCLC tissues have revealed that these tumors display
a strikingly high rate of protein-changing mutations (Peifer et al.,ant progress in the development of SCLC therapies since the
mors exhibit a complex genome with a high mutation rate,
ggable oncogenes. Herewe find that inhibitors of the general
(THZ1), potently suppress SCLC growth. We identify a num-
-associated proto-oncogenic and lineage-specific transcrip-
ensitivity. Our data suggest that THZ1 can effectively target
erapeutic window for effective SCLC therapy.
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mutations have been identified to guide therapeutic decisions
for SCLC, and efficient treatment paradigms are urgently needed.
SCLC is defined by the near ubiquitous inactivation of both
P53 and RB (Peifer et al., 2012; Rudin et al., 2012; Sato et al.,
2007); however, recent reports indicate that the cell of origin is
equally important for the development of SCLC disease. Condi-
tional inactivation of p53 and Rb in the adult mouse lung, using
a genetically engineered mouse (GEM) model, is sufficient to
develop murine SCLC (mSCLC) resembling human disease
(Meuwissen et al., 2003). Importantly, though, SCLC is firmly es-
tablished only if P53 and RB are inactivated in the small popula-
tion of pulmonary neuroendocrine cells (PNECs) (Sutherland
et al., 2011). In contrast, P53 and RB loss confined to the abun-
dant nonneuroendocrine cell population in the murine lungs
causes low penetrance of SCLC and a significant increase in dis-
ease latency (Park et al., 2011; Sutherland et al., 2011). Thus, the
PNEC is the major cell of origin of SCLC, suggesting that neuro-
endocrine pathways collaborate with P53 and RB loss to initiate
and drive SCLC tumorigenesis.
SCLC cells (as well as PNECs) exhibit high, sustained expres-
sion of many neuroendocrine genes, in particular transcription
factors that regulate neuroendocrine development and differenti-
ation in various tissues (Pedersen et al., 2003; Reynolds et al.,
2000; Travis, 2009). Achaete-scute homolog 1 (ASCL1) is a mas-
ter regulator of neuroendocrine differentiation in lung develop-
ment (Borges et al., 1997; Ito et al., 2000) and has been shown
to regulate tumor-initiating capacity and survival pathways in
SCLC (Jiang et al., 2009; Osada et al., 2005), hence underscoring
the interplay between neuroendocrine signaling and SCLC path-
ogenesis. Furthermore, the lineage-specific transcription factor
NEUROD1 has been reported to govern survival pathways in
SCLC cells (Osborne et al., 2013). Further, SCLC cells exhibit
various chromosomal and focal amplifications leading to
increased target gene expression and possible gain of function.
Fifty to eighty percent of SCLC tumors exhibit mutually exclusive
amplification of the proto-oncogene MYC, MYCN, or MYCL
(Brennan et al., 1991; Huijbers et al., 2014; Johnson et al., 1987;
Kim et al., 2006; Peifer et al., 2012; Rudin et al., 2012; Voortman
et al., 2010). MYC is misregulated in the majority of human can-
cers, leading to uncontrolled proliferation possible through
augmentation of existing gene expression programs (Lin et al.,
2012). In contrast toMYC,MYCN andMYCLmisregulation occurs
only in high-risk cancers of neuroendocrine origin, such as SCLC
(Huijbers et al., 2014; Johnson et al., 1987; McFadden et al.,
2014), neuroblastoma (MYCN) (Huang andWeiss, 2013), andme-
dulloblastoma (MYCN, MYCL) (Northcott et al., 2012). Moreover,
many SCLC tumors have focal amplifications or increased
expression of SOX-family genes (Voortman et al., 2010), including
SOX2, which is critical for lung development and self-renewal.
SOX2 amplification and increased expression levels in tumors
correlate with accelerated disease stage, and silencing of SOX2
inhibits growth of SCLC cells (Rudin et al., 2012).
Thus, misregulated and amplified lineage-specific and proto-
oncogenic transcription factors appear to govern SCLC initiation
and disease evolution, and downregulation of such factors could
form the basis for SCLC targeted therapy.
Using an unbiased small-molecule screen approach, we
indeed observed that SCLC is highly sensitive to transcription-910 Cancer Cell 26, 909–922, December 8, 2014 ª2014 Elsevier Inc.targeting drugs and in particular to a covalent inhibitor of cy-
clin-dependent kinase 7 (CDK7), THZ1, which can drastically
reduce RNAPII-mediated gene transcription (Kwiatkowski
et al., 2014). Here, we sought to investigate the therapeutic po-
tential of THZ1 in SCLC preclinical models and further use
THZ1 as a chemical tool to dissect the malignant transcriptional
programs driving SCLC state.
RESULTS
High-Throughput Small-Molecule Drug Screen
Identifies THZ1 as a Highly Potent Inhibitor of SCLC
Viability
To identify small molecules that suppress SCLC cell growth, we
performedanunbiasedhigh-throughput screen inSCLCcell lines
using a library of greater than 1,000 annotated small-molecule in-
hibitors composed of both experimental compounds and early or
advanced stage clinical candidates. To minimize artifacts that
may arise from long-term culture of SCLC cell lines, we used
low-passage (passage 5–10), primary mSCLC cell lines, estab-
lished from mSCLC tumors isolated from the GEM model of
SCLC consisting of the RbL/L;p53L/L (RP) allelic genotype (Meu-
wissen et al., 2003) (Figure 1A). To account for tumor heterogene-
ity, a total of three mSCLC cell lines (termed mSCLC1, mSCLC2,
and mSCLC3), each from a different tumor-bearing RP mouse,
were used to establish cell lines for the screen (Figure 1A). Impor-
tantly, all established mSCLC cell lines displayed morphology
that is characteristic of SCLC by growing as suspension cells in
floating aggregates and spheres (Figure 1A). Furthermore, the
established mSCLC cells expressed classical SCLC-specific
(neuroendocrine) markers (Figure S1A available online). Using a
cell viability assay, compounds were initially screened at a
single dose on the mSCLC cells. Forty-five compounds elicited
greater than 50% reduction in growth andwere triaged for further
inspection (Figure 1B). Fifteen compounds resulted in a mean
antiproliferation half maximal inhibitory concentration (IC50)
across three SCLC cell lines of less than 300 nM (Figure 1C).
The top-ranked inhibitors fell broadly into three major putative
categories of inhibitors of (1) transcription (THZ1, flavopiridol,
CGP60474, JQ1, NVP-AUY922, 17-DMAG, and BI2536), (2) cell
cycle function (BI2536, CGP60474, AZD7762, ON-01910,
PF477736, XMD16-144, and THZ1), and (3) the mTOR-PI3K
pathway (GSK2126458, PIK75, and Torin 2) (Figures 1C and 1D).
SCLC cell lines demonstrate particular sensitivity to transcrip-
tional inhibition with the top 3 scoring small-molecule inhibitors
from the screen (NVP-AUY922, BI2536, and THZ1) targeting pro-
teins involved in transcriptional regulation. NVP-AUY922 targets
HSP90, which has recently been shown to be involved in regu-
lating RNAPII pausing and transcriptional activation (Sawarkar
et al., 2012). BI-2536, known as a Polo-like 1 (PLK1) kinase inhib-
itor, has recently been shown to cross-react with bromodomain
(BRD) 4, a general coactivator of gene expression (Ember et al.,
2014). The BRD inhibitor JQ1 (Filippakopoulos et al., 2010) also
ranked within the top 15 inhibitors (Figure 1C). Disappointingly,
however, despite displaying efficacy in tumor cell lines, clinical
trials with both HSP90 inhibitors and PLK1 inhibitors have in gen-
eral fared poorly. As a result, we focused much of our attention
on THZ1, a recently identified covalent CDK7 inhibitor with addi-
tional cross-reactivity against CDK12/13. THZ1 has recently
Figure 1. High-Throughput Drug Screen in Primary mSCLC Cell Lines Identifies THZ1 as a Highly Potent Inhibitor of SCLC Cell Viability
(A) mSCLC cell lines (mSCLC1, mSCLC2, and mSCLC3) were established from three different Ad-Cre-induced RP mice aged 8 to 10 months. Representative
morphology of established primary mSCLC cells is shown to the right. Black scale bar shown in micrographs represents 50 mm.
(B) More than 1,000 small-molecule inhibitors were included in a high-throughput screen using mSCLC1, mSCLC2, andmSCLC3 cell lines at passage 5 to 10. All
drugs were added to each cell line (day 0) at a concentration of 600 nM, and cell viability wasmeasured at day 5, allowing for two doubling cycles of (control) cells.
The inhibitors that reduced cell viability by 50% (compared with no drug control) were further ranked following dose escalation treatment to determine the IC50 of
cell viability. Fifteen compounds had IC50 values below 300 nM according to both cell viability assays.
(C) Summary of top 15 ranked small molecules and corresponding targets as represented in an ‘‘IC50 heatmap’’ format.
(D) Distribution of putative targets of top 15 ranked small molecules with targets categorized as regulating (1) transcription (green bar), (2) cell cycle (yellow bar), or
(3) PI3K-mTOR pathway (brown bar).
(E) mSCLC and mNSCLC cell lines (mNSCLC1: Kras+/LSL-G12D;p53L/L, mNSCLC2: Kras+/LSL-G12;p53L/L;Lkb1L/L) were incubated with increasing doses of THZ1,
and IC50 values were measured by cell viability assay. Data are presented as mean ± SEM.
See also Figure S1.
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kemia viability, in part, through downregulation of key oncogenic
transcription factors (Kwiatkowski et al., 2014). We speculated
that the high ranking of THZ1 in the drug screen could indicate
that SCLC exhibits similar dependencies for the expression of
oncogenic transcription factors.
We compared the observed effects of THZ1 in mSCLC cells
with that of mutant Kras-driven murine NSCLC (mNSCLC) cell
lines (Liu et al., 2013). THZ1 displayed an IC50 value of 75 to
100 nM against mSCLC cells, while mNSCLC cells had a higherCaIC50 of about 750 nM (Figure 1E). These data suggest that lung
cancer types addicted to mutated kinases are relatively less
vulnerable to transcription-targeting drugs than SCLC. When
testing several commercially available pan-CDK inhibitors tar-
geting one or more of the higher order transcriptional CDKs
such as CDK7, CDK8, and CDK9, we found that apart from fla-
vopiridol and dinaciclib, all compounds had an IC50 exceeding
500 or 1,000 nM (Figures S1B–S1D). Dinaciclib and flavopiridol
showed potency at a nanomolar scale similar to that of THZ1
but did not exhibit SCLC specificity, as Kras-driven NSCLC cellncer Cell 26, 909–922, December 8, 2014 ª2014 Elsevier Inc. 911
Figure 2. THZ1 Treatment of RP Mice Causes Significant Tumor Response and Increased Survival
(A) Schematic overview of treatment trial with vehicle (control), THZ1, or Cis-Eto compared with vehicle (control) in RP mice with confirmed (by MRI) SCLC
disease. THZ1 is dosed at 10mg/kg twice daily, and Cis-Eto is dosed as follows: cisplatin 5mg/kg once per week, etoposide 10mg/kg three times per week. Cis-
Eto is given 1 to 2weeks on (pending weight and toxicity) and thereafter 2 to 3weeks off, followed by 1 to 2weeks retreatment (pendingweight, toxicity, and tumor
burden according to MRI). After treatment start, MRI was performed biweekly in all treatment cohorts.
(legend continued on next page)
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S1C). As previously observed (Kwiatkowski et al., 2014), THZ1
facilitated irreversible (covalent) binding to CDK7 (Figure S1E),
and a noncovalent version of THZ1 (THZ1-R) was significantly
less potent (Figure S1F). Hence, THZ1 potently and selectively
inhibits SCLC cell viability, and its induced cellular effects result,
in part, from its irreversible covalent inhibition of CDK7. Both fla-
vopiridol and THZ1 have been shown to cross-react with
CDK12/13 at higher concentrations (Bo¨sken et al., 2014; Kwiat-
kowski et al., 2014); therefore, this shared pharmacology may
also affect the transcriptional and phenotypic response of
SCLC to these inhibitors.
Mice with Aggressive Autochthonous SCLC Disease
Show Significant Tumor Response following THZ1
Treatment
To establish the translational significance of the observed po-
tency of THZ1 in mSCLC cells, we tested THZ1 in vivo in the
RP GEM model. This autochthonous mouse model offers a pre-
clinical platform with remarkable resemblance to the human
SCLC (hSCLC) disease (Meuwissen et al., 2003). The concomi-
tant loss of p53 and Rb function in the adult murine lung tissue
allows for a stochastic and heterogeneous disease course with
aggressively growing primary lung tumor and metastasis. Dis-
ease course in RPmicewas followed byMRI of the thorax region,
and upon detectable lung tumor burden, mice were started on
treatment with either THZ1 or vehicle. We additionally treated a
cohort of mice with cisplatin and etoposide (Cis-Eto) to allow
comparison with the standard-of-care chemotherapeutic re-
gimen used in the clinic for SCLC patients. MRI was performed
every 2 weeks after treatment began in the three different treat-
ment cohorts (Figures 2A–2F). All vehicle-treated mice showed
progressive disease (PD; a more than 20% increase in tumor vol-
ume compared with baseline), with mean tumor volume doubling
after a 2-week period (Figures 2B and 2F). THZ1-treated mice
had significant tumor response compared with control at the
2-week time point (Figures 2B, 2C, 2F, and S2A). Three of nine
THZ1-treated mice showed partial response (PR; a more than
30% tumor volume reduction compared with baseline), and two
of those had near complete response, with more than 90%
reduction in tumor burden. Four THZ1-treated mice had stable(B) Tumor volume changes (%) according to MRI quantification in vehicle-trea
normalized to pretreatment (week 0) tumor volume. The p values between differe
individual values for tumor volume change at 2 weeks (dots) and 4 weeks (squar
(C) Treatment response divided into PD, SD, and PR groups inmice treated with v
respective treatment cohort.
(D) Toxicity events observed inmice treatedwith THZ1 or Cis-Eto asmeasured by
with pretreatment weight) during the treatment study, the animal was recorded to
treatment cohort.
(E) Survival of control, THZ1-treated, and Cis-Eto-treated mice. The p value was
(F) Representative magnetic resonance images of the thorax regions of mice tre
(G) Representative 203 fieldmicrographs (insets, 403 field) of TUNEL staining of lu
scale bar in micrographs (203) represents 50 mm. Black scale bar in insets (403
(H) Primary (lung) and metastatic (liver) SCLC lesions were isolated from Ad-Cre-
(primary) andmetastatic (liver tumor) origin were incubatedwith increasing doses
from several different cell lines of either group are plotted to give a total calculat
(I) SCLC tumor lesions from the lung were isolated from untreated RP mice (n = 2
cells (at passage 5) were incubated with increasing doses of Cis-Eto (right) or THZ
from several different cell lines of either group are plotted (squares or dots) to giv
See also Figure S2.
Cadisease (SD; neither a reduction nor an increase in tumor volume
to classify as PR or PD), while two THZ1-treated mice had PD.
Further, the majority of THZ1-treated mice with SD or PR at the
2-week time point had similar disease responses at the 4-week
time point (Figures 2B, 2C, 2F, and S2A). In contrast, most
vehicle-treated mice succumbed to their tumor burden before
the 4-week time point (four of six mice), emphasizing the aggres-
sive disease course in the SCLCGEMmodel (Figures 2B and 2E).
Overall, THZ1-treated mice had longer survival compared with
control-treated mice (p = 0.0011) (Figure 2E). Furthermore, we
observed that response rates and survival obtained from sin-
gle-agent THZ1 treatment were comparable with tumor response
rates upon standard-of-care chemotherapy (Figures 2B–2F).
However, THZ1 treatment did not result in treatment-related
toxicity in RP mice in contrast to Cis-Eto treatment (Figure 2D).
The lack of observed toxicity in THZ1-treated mice suggests
that THZ1 treatment allows a broader therapeutic window in can-
cer versus normal cells compared with chemotherapy.
To investigate whether single-agent activity of THZ1 or Cis-Eto
could be augmented by a combined treatment regimen, we
treated an additional cohort of RP mice with THZ1 combined
with Cis-Eto. Our results indicate that mice treated with THZ1
and Cis-Eto do not experience superior tumor response at
the 4-week time point compared with mice receiving THZ1 or
Cis-Eto alone (Figures S2B–S2E). Of note, we did not observe in-
creased toxicity in mice treated with THZ1 and Cis-Eto com-
pared with Cis-Eto treatment alone (Figure S2C).
THZ1 treatment resulted in decreased RNAPII CTD phosphor-
ylation in SCLC tumor tissue compared with vehicle-treated
mice (Figure S2F), consistent with THZ1 binding and inhibition
of CDK7 in tumor tissue. Tissue from both lung tumors (n = 3)
and liver metastases (n = 1) isolated from THZ1-treated mice
had significantly more apoptotic cells than vehicle-treated tumor
tissue as measured by TUNEL staining (Figures 2G and S2G).
Additionally, mSCLC cells established from SCLC lung tumors
and from liver metastases showed equal sensitivity to THZ1,
indicating that both primary and metastatic SCLC lesions are
responsive to THZ1 treatment (Figure 2H). Importantly, we found
that mSCLC cells established from tumors from chemotreated
(resistant) SCLC RP mice had similar sensitivity to THZ1
compared with mSCLC cell lines established from untreatedted (control), THZ1-treated, and Cis-Eto-treated mice at 2 and 4 weeks as
nt treatment cohorts were calculated using Student’s t test. Data are shown as
es), with horizontal line representing means.
ehicle (control), THZ1, or Cis-Eto. Data are shown as percentage of total mice in
weight loss in mice. If an animal’s weight decreased to 15%ormore (compared
have treatment-induced toxicity. Data are shown as percentage of total mice in
established using log rank test (Mantel-Cox test).
ated with vehicle (control), THZ1, or Cis-Eto at 2 and 4 weeks.
ng tumor and liver metastases 72 hr after treatment with THZ1 or vehicle. Black
) represents 25 mm.
induced RP mice for cell line establishment. Cells established from lung tumor
of THZ1, and the IC50 values were determined by cell viability assay. IC50 values
ed mean IC50 (horizontal line), with error bars representing SD.
) and chemotreated mice (n = 2) for establishment of primary cell lines. Primary
1 (left), and the IC50 values were determined by cell viability assay. IC50 values
e a total calculated mean IC50 (horizontal line), with error bars representing SD.
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both chemonaive and chemorefractory SCLC disease is sensi-
tive to THZ1 treatment.
Cellular and Tumor Models of hSCLC with Distinct
Genotypes andPhenotypes AreHighly Sensitive to THZ1
To further confirm THZ1 as a drug candidate for patient disease,
we investigated THZ1 potency in a panel of genotypically-
distinct hSCLC cell lines. hSCLC cell lines are known to harbor
a complex genome with a high mutation rate, frequent copy
number gains and losses, and translocations (Peifer et al.,
2012; Pleasance et al., 2010; Rudin et al., 2012). The major iden-
tified alterations in the hSCLC cell lines, apart from themutations
in P53 and RB, include amplification of MYC, MYCL, or MYCN
(Johnson et al., 1987). We used a panel of hSCLC cell lines
harboring amplifications in each of theMYC genes. Additionally,
we investigated SCLC tumor cells from chemonaive and chemo-
treated patients as well as those isolated from primary lung sites
and from metastatic lesions (Figure 3A). All hSCLC cell lines ex-
hibited high sensitivity to THZ1, with IC50 values in the range of 5
to 20 nM (Figure 3A [all], Figure 3B, top [representative]). The
NCI-H69, GLC16, and NCI-H82 cell lines established from che-
motreated patients were less sensitive to Cis-Eto treatment
than the chemonaive cell line NCI-H209 (Figure 3B, bottom).
THZ1 treatment of tumor xenografts established from NCI-H69
and GLC16 cells resulted in significant tumor growth reduction
compared with control-treated tumors, indicating that chemore-
fractory disease is sensitive to THZ1 treatment (Figure 3C). As in
GEM mice, no overt toxicity was observed from THZ1 treatment
(Figure 3C, insets). In contrast to hSCLC cells, immortalized
tracheobronchial epithelial (hTBE) cells showed very little sen-
sitivity to THZ1 but similar sensitivity to Cis-Eto (Figure 3B), rein-
forcing previous observations that THZ1 treatment confers a
superior therapeutic window between cancer and noncancer
cells compared with chemotherapy.
Substantial induction of apoptosis was observed in hSCLC
cells as early as 6 hr after exposure to THZ1 (Figure 3D), and in-
hibition of proliferation occurred at 24 and 48 hr after exposure
(Figure 3E). The appearance of apoptotic markers appeared
concomitant with the decrease of RNAPII CTD phosphorylation
(Figures 3D and 3F). In line with these results, we observed
that the classical sphere-forming morphology of SCLC cells
was dramatically disrupted after only 12 hr of exposure to
THZ1 in 3D culture (Figure S3A). Similar differential sensitivity
was observed between hSCLC and hNSCLC cells (Figures
S3B–S3E), as previously noted in the murine cellular lung cancer
models (Figure 1E). As observed in the mSCLC cell lines, most
pan-CDK inhibitors tested showed either less potency in hSCLC
cells or less SCLC specificity (Figures S3C–S3E). Furthermore,
we observed significantly lower potency of THZ1-R compared
with THZ1, again confirming that the covalent mechanism of
action of THZ1 is critical for drug potency (Figure S3F–S3G).
THZ1 Confers Preferential Repression of
Transcription-Regulating Genes in SCLC Cells
Intrigued by the significant therapeutic response in various pre-
clinical models of SCLC disease, we aimed to understand the
mechanisms governing SCLC sensitivity to THZ1. CDK7 is a
component of the general transcription factor IIH, which activates914 Cancer Cell 26, 909–922, December 8, 2014 ª2014 Elsevier Inc.RNAPII-mediated transcription. Consistent with this notion, high-
dose treatment with THZ1 in Jurkat cells was previously shown to
cause pronounced global downregulation of gene expression;
however, low-dose THZ1 produced gene-selective effects on
the Jurkat interconnected transcriptional core regulatory circuitry
(Kwiatkowski et al., 2014). To investigate THZ1-induced tran-
scriptional effects in SCLC, we performed gene expression
profiling in selected hSCLC cell lines (NCI-H69, GLC16, and
NCI-H82), following treatment with 25 and 100 nM THZ1, which
are concentrations at which limited and substantial inhibition of
RNAPII phosphorylation is achieved, respectively (Figure 3F).
Across SCLC cell lines, treatment with THZ1 led to a reduction
in steady-state mRNA levels with 0.2% to 5% and 13% to 27%
of mRNAs showing greater than 2-fold reduction at 25 and
100 nM, respectively (Figures 4A and 4B; Tables S1 and S2).
Gene ontology (GO) analysis revealed a significant enrichment
of genes involved in transcription among the top 5% of downre-
gulated genes after 100 nMTHZ1 treatment (Figure 4C). In partic-
ular the major part of THZ1-sensitive transcripts is associated
with DNA-dependent transcription, indicating transcription factor
function (Figure 4C). Moreover, gene set enrichment analysis of
transcription factor binding sites showed that genes containing
binding motifs for transcription factors such as E2F, NRF1, and
CREB were preferentially affected by THZ1 treatment (Fig-
ure S4A). In particular, we observed that short-lived transcripts
of the E2F family were heavily downregulated and that E2F-
regulated gene sets were significantly enriched in THZ1-downre-
gulated transcripts (Figures S4B and S4C). Interestingly, E2F
transcription factor binding sites are significantly enriched in
the SCLC cells compared with the NSCLC cells (Figures S4D
and S4E), suggesting that E2F transcription factors have a
more prominent role in SCLC biology.
Proto-Oncogenic and Lineage-Specific Transcription
Factors Are Associated with Super-Enhancers in SCLC
Little is known about the transcription factors and cofactors that
govern the pathogenesis of SCLC. Genes encoding important
regulators of cell state, including key oncogenic transcription
factors, were recently shown to be preferentially associated
with unusually large transcriptional regulatory domains known
as super-enhancers (Hnisz et al., 2013; Love´n et al., 2013).
Furthermore, previous work has demonstrated that expression
of super-enhancer-associated genes can be especially vulner-
able to transcriptional inhibitors (Chapuy et al., 2013; Hnisz
et al., 2013; Kwiatkowski et al., 2014; Love´n et al., 2013; Whyte
et al., 2013). Therefore, the identification of super-enhancers in
SCLC may enumerate candidate SCLC oncogenes and focus
our search for THZ1-responsive transcripts whose downregula-
tion lead to loss of SCLC cell state.
To identify super-enhancers in SCLC cells, we performed
chromatin immunoprecipitation sequencing (ChIP-seq) against
the lysine 27 acetylated form of histone H3 (H3K27Ac) in un-
treated hSCLC cells. H3K27Ac defines active enhancers and
has been used previously to determine the positions and sizes
of super-enhancers (Hnisz et al., 2013). Using this approach,
we identified 130 super-enhancer-associated genes in NCI-
H69, 103 inGLC16, and 70 inNCI-H82 (Figures 5A–5D; Table S3).
We found that many super-enhancer-associated genes en-
code gene products involved in regulation of RNAPII-mediated
Figure 3. THZ1 Is a Potent Inhibitor of Cell Viability and TumorGrowth in a Panel of Genotypically and Phenotypically Distinct SCLCCell Lines
and Xenografts
(A) Summary of THZ1 IC50 values in the full panel of SCLC cell lines with genotype and phenotype status. IC50 data are presented asmeanwith confidence interval
(CI). Phenotype profile information on cell lines comprises the following: origin—organ of origin of tissue specimen from which cell line was established;
chemotherapy—whether patients had received chemotherapy before cell line establishment (yes or no). Genetic profile information on cell lines includes P53 and
RBmutations (both leading to loss of function) andMYC gene family amplification (C-MYC,MYCN, orMYCL). Asterisk indicates that cell lines have previously been
classified as ‘‘variant’’ neuroendocrine SCLCcell line on the basis of the lack of expression of ‘‘classical’’ neuroendocrine genes such asASCL1,NCAM, andSCG2.
(B) Representative hSCLC cell lines (from A) and the hTBE cell line were exposed to increasing doses of THZ1 (top) or Cis-Eto (bottom), and IC50 values were
determined by cell viability assay. Each data point is shown as mean ± SEM. Mean IC50 values to Cis-Eto treatment are reported next to cell line name (bottom).
(C) Tumor volume index of hSCLC xenografts grown on nude mice (NCI-H69, left; GLC16, right) as normalized to pretreatment volume (day 0). Mice were treated
with vehicle or THZ1. THZ1 was dosed at 10 mg/kg twice daily and vehicle twice daily. Insets show weights from mice on treatment.
(D) Apoptosis assay measuring caspase-3/7 activity in the SCLC cell line NCI-H69 after THZ1 treatment for indicated time points.
(E) Proliferation assay measuring BRDU incorporation in SCLC cell line NCI-H69 after THZ1 treatment for indicated time points.
(F) Western blot detecting RNAPII, CTD phosphorylation (SER-2, SER-5, and SER-7), and CDK7 along with the apoptotic markers caspase-3 and PARP in total
protein lysates from NCI-H69 cell lines exposed to indicated doses of THZ1. ACTIN serves as a loading control.
See also Figure S3.
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Targeting Transcriptional Addictions in SCLCtranscription (Figures 5A and 5B). This indicates that many
transcription factors are important to SCLCstate andmight repre-
sent candidate oncogenes.
The super-enhancer landscape recapitulated the embryonic
and neural signature common to SCLC cells. Many super-en-Cahancers were found to be associated with genes encoding line-
age-specific transcription factors that are central regulators of
embryogenesis and neural development (Figures 5A and 5B).
Consistent with previous investigations observing differential
gene expression profiles between the so-called classical andncer Cell 26, 909–922, December 8, 2014 ª2014 Elsevier Inc. 915
Figure 4. THZ1 Treatment Preferentially Targets Transcription-Regulating Genes in SCLC Cells
(A) Heatmap displaying the log2 fold change in gene expression versus DMSO for all active transcripts in NCI-H69, GLC16, and NCI-H82 cells following treatment
with 25 and 100 nM THZ1 for 6 hr.
(B) Box plots of log2 fold change in gene expression versus DMSO for all active transcripts in NCI-H69, GLC16, and NCI-H82 cells following treatment with 25 or
100 nM THZ1 for 6 hr. Whiskers extend to 1.5 times the interquartile range.
(C) Enrichment p values for selected GO functional categories of top 5% downregulated genes (versus DMSO) of all active transcripts in NCI-H69, GLC16, and
NCI-H82 cells following treatment with 100 nM THZ1 using DAVID software.
See also Tables S1 and S2 and Figure S4.
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Targeting Transcriptional Addictions in SCLCvariant SCLC cell lines (Johnson et al., 1987; Pedersen et al.,
2003), we found that the ‘‘classical’’ GLC16 and NCI-H69 cell
lines had significant overlap in identified super-enhancer genes,
while the ‘‘variant’’ NCI-H82 cell line had a super-enhancer profile
distinct from that of the classical cell lines (Figures 5B and 5C).
In both NCI-H69 and GLC16 cell lines, we identified super-en-
hancers associated with SOX2 and NFIB (Figures 5A and 5D),
consistent with their proposed role as proto-oncogenic tran-
scription factors in SCLC (Dooley et al., 2011; Rudin et al.,
2012). Similarly, the neuroendocrine master transcription factor
gene ASCL1 (Borges et al., 1997; Ito et al., 2000) was associated
with one of the largest typical enhancers (TEs) (Figures 5A and
5D; Table S2). Moreover, we identified many super-enhancer-
associated transcription factor genes in GLC16 and NCI-H69
whose functions were not previously described in the context
of SCLC biology. Among them was Insulinoma-associated 1
(INSM1) (Figures 5A and 5D; Table S3), whose expression repre-916 Cancer Cell 26, 909–922, December 8, 2014 ª2014 Elsevier Inc.sents a highly predictive marker of SCLC disease (Figure S5)
(Christensen et al., 2010; Lan and Breslin, 2009; Pedersen
et al., 2003). In the NCI-H82 cell line, we identified a super-
enhancer at theOTX2 gene, which encodes a transcription factor
involved in neural differentiation and development. Similar to
INSM1, the functional role of OTX2 in SCLC biology is unknown.
Moreover, we identified large TEs associated with the proto-
oncogenic neuroendocrine transcription factor genesNEUROD1
(Figures 5A, 5D, and S5; Table S3) (Osborne et al., 2013).
Super-enhancers were found to be associated with genes that
had focal amplification. The C-MYC amplified cell lines GLC16
and NCI-H82 and the MYCN amplified cell line NCI-H69 (Fig-
ure 3A) had super-enhancers associated with C-MYC and
MYCN gene loci, respectively (Figures 5A and 5D). In the NCI-
H69 cell lines, theMYCN super-enhancer ranked second largest,
and in NCI-H82, the two largest super-enhancers were both
found in the C-MYC gene loci (Table S3). Interestingly, we also
Figure 5. Super-Enhancers in hSCLC Cell Lines Are Associated with Proto-Oncogenic and Lineage-Specific Transcription Factor Genes
(A) Distribution of H3K27Ac signal at enhancers. Enhancer regions are plotted in increasing order on the basis of their input-normalized H3K27Ac signal (length3
density) in NCI-H69, GLC16, and NCI-H82 cell lines.
(legend continued on next page)
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Targeting Transcriptional Addictions in SCLCfound evidence for focal amplification of OTX2 in the NCI-H82
cell line (Figure 5D).
Super-Enhancer-Associated Genes Are
Disproportionally Vulnerable to THZ1 Treatment
Next we aimed to investigate whether THZ1 conferred preferen-
tial downregulation of super-enhancer-associated genes in
SCLC (Figures 6A–6C). Enrichment analysis of THZ1-sensitive
transcripts (Figure 4; Table S2) and super-enhancer-associated
genes (Table S3) showed that THZ1-targeted transcripts are en-
riched in the gene sets with associated super-enhancers (false
discovery rate < 0.05) (Figure 6A; Table S4). Moreover, mean
transcript abundance associated with super-enhancers was
disproportionately reduced upon THZ1 exposure compared
with that of TEs (Figure 6B). This disproportionate reduction
was observed even at the low dose (25 nM) of THZ1, which pro-
duces limited repression of RNAPII-mediated transcription (Fig-
ure 3F). In addition, genes associated with the top-ranked
(largest) TE (TOPTE) were more sensitive to THZ1 treatment
than genes associated with a general TE (Figure 6B), empha-
sizing that enhancer size is positively correlated with THZ1
vulnerability.
In order to focus our search for SCLC oncogenic transcription
factors, we identified a leading-edge gene set from our enrich-
ment analysis (Figure 6A), consisting of super-enhancer-associ-
ated core enrichment genes that were downregulated by THZ1
(Figure 6C). Because oncogenic transcription factors are often
highly expressed, we further filtered our leading-edge gene set
(Figure 6C) to contain the top 5% actively expressed genes (Fig-
ure 6D). Confirmative of this scheme, the MYC-family of proto-
oncogenes placed among the leading-edge gene set and was
among the top 5%most actively expressed genes in the analyzed
hSCLCcells (Figure6D).Using this approach,we further identified
SOX2, SOX4, INSM1 (NCI-H69, GLC16), and OTX2 (NCI-H82).
ASCL1 (NCI-H69, GLC16) andNEUROD1 (NCI-H82) both associ-
ated with a TOPTE but were both highly reduced in THZ1-treated
cells and ranked among the top 5% actively expressed genes
(Figures 6C and 6D). The downregulation of the transcription fac-
tor genes was confirmed on the RNA level by quantitative PCR
(Figure 6E), and selected transcripts further confirmed on the pro-
tein level (Figure 6F). The reduced transcript level of SCLC-spe-
cific transcription factors observed in vitro was furthermore
confirmed in vivo in THZ1-treated RP mice (Figure S6).
DISCUSSION
Here, we addressed a high therapeutic need by identifying THZ1
(Kwiatkowski et al., 2014) as a promising drug candidate for the
treatment of SCLC. Although recent sequencing efforts revealed
that SCLC tumors contain a high rate of protein-altering muta-
tions, the mapping of the mutational landscape did not guide(B) Enrichment p values for selected GO functional categories of super-enhance
(C) Venn diagram showing overlap between identified super-enhancer genes be
(D) Gene tracks of H3K27Ac ChIP-seq occupancy at super-enhancer-associated
genomic position and the y axis shows the signal of binding in 50 bp bins in uni
(MYCN [NCI-H69], MYC [NCI-H82, GLC16]), input DNA signal-subtracted H3K2
models are depicted below each track set.
See also Table S3 and Figure S5.
918 Cancer Cell 26, 909–922, December 8, 2014 ª2014 Elsevier Inc.in therapeutic decisions for this fatal disease (Peifer et al.,
2012; Rudin et al., 2012). Using an unbiased small-molecule
screen approach, we observed that SCLC cells were highly
vulnerable to perturbation of the transcriptional state as several
transcriptional inhibitors were potent inhibitors of SCLC cell
viability. The high potency of THZ1 in SCLC cells was further
confirmed in vivo in the RP GEM mice model, which represents
a highly translational preclinical platform for the investigation of
SCLC therapeutics (Meuwissen et al., 2003). The RPGEMmodel
mimics the stochastic and heterogeneous pathogenesis in hu-
man disease, and mSCLC tumors have been shown to accumu-
late additional alterations, as observed in human disease, such
as amplification of MYCL (McFadden et al., 2014; Peifer et al.,
2012). We observed significant tumor responses in SCLC GEM
mice treated with THZ1 compared with control-treated mice
and further noted that standard-of-care chemotherapy caused
similar response rates in SCLC GEM mice. However, although
chemotherapy was associated with toxicity, THZ1 treatment
did not cause any overt toxicity in treated mice. Furthermore
our treatment data in both murine and human preclinical models
of SCLC indicate that both metastatic and chemorefractory
SCLC disease are sensitive to THZ1 treatment.
The encouraging preclinical results led us to investigate
the transcriptional addictions of SCLC. Because of the pre-
ponderance of misregulated transcription factors in SCLC
(Dooley et al., 2011; Jiang et al., 2009; Johnson et al., 1987;
Osborne et al., 2013; Pedersen et al., 2003; Rudin et al., 2012;
Voortman et al., 2010), we aimed to identify a candidate list of
transcription factor genes associated with super-enhancers
(Chapuy et al., 2013; Hnisz et al., 2013; Kwiatkowski et al.,
2014; Love´n et al., 2013; Whyte et al., 2013) and whose high-
level expression was particularly vulnerable to THZ1 treatment.
We hypothesized that such a list would represent candidate
oncogenic transcription factors in SCLC disease.
Affirmative of this scheme, we identified that the focally ampli-
fiedC-MYC (in GLC16 andNCI-H82 cells) andMYCN (in NCI-H69
cells) proto-oncogenes (Brennan et al., 1991; Voortman et al.,
2010) were associated with large super-enhancers and were
highly vulnerable to THZ1. We did not observe differential sen-
sitivity to THZ1 between SCLC cells with genomic amplification
of MYCN, C-MYC, or MYCL and cell lines without amplification,
therefore suggesting that MYC amplification is not a biomarker
per se for THZ1-sensitive SCLC. Because focal amplification of
MYC gene members is associated with later stage disease and,
possibly, chemoresistant disease (Brennan et al., 1991; Johnson
et al., 1987), these data further support that THZ1 treatment will
be effective in progressive SCLC disease stages.
In contrast to MYC amplifications, the transcriptional-ampli-
fied neuroendocrine gene program is an early and possible
contributing event of SCLC disease, in which PNECs are
believed to be the cell of origin (Park et al., 2011; Sutherlandr-associated genes in NCI-H69, GLC16, and NCI-H82 cell lines using DAVID.
tween NCI-H69, GLC16, and NCI-H82 cell lines.
(top two rows) and TE-associated (bottom row) gene loci. The x axis shows
ts of reads per million bin (rpm/bin). For genes with known focal amplification
7Ac signal is displayed (see Supplemental Experimental Procedures). Gene
(legend on next page)
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where they play a role in lung branching morphogenesis and ox-
ygen sensing. The purpose and function of the small population
(<0.5%) of PNECs maintained in the adult lung epithelium is not
known (Reynolds et al., 2000; Travis, 2009). Although the neuro-
endocrine signature of SCLC has been a central diagnostic tool,
only a few functional studies have been performed to explore if
and how the malignant neuroendocrine factors contribute to
SCLC disease (Ball, 2004; Lan and Breslin, 2009). We identified
a TOPTE associated with ASCL1, in support of its established
role as a master transcription factor in lung neuroendocrine dif-
ferentiation (Borges et al., 1997) and as a proposed candidate
oncogene in SCLC (Jiang et al., 2009). Our results greatly corrob-
orate these findings as we observe that ASCL1 is among the top
2%most downregulated genes in THZ1-treated cells. We further
identified several candidate oncogenic transcription factors in
SCLC. One example is the neuroendocrine transcription factor
INSM1, which is represent a highly lineage-defining trait of
SCLC. INSM1 phenocopies ASCL1 function in murine neural
development, but it is not known whether the same functional
link exists in SCLC biology (Ball, 2004; Lan and Breslin, 2009).
Future work should investigate the role of INSM1 and other tran-
scription factors in the malignant transcriptional gene programs
that drive and maintain SCLC disease.
Our chemical screen revealed that 7 of 15 compounds iden-
tified as potent inhibitors of SCLC cell viability are transcrip-
tional inhibitors. Hence, further pharmacological studies of
small molecules targeting the general transcription apparatus
should be performed to advance the field of SCLC-tailored
therapeutics and to uncover the transcriptional addictions of
SCLC.
EXPERIMENTAL PROCEDURES
Generation of GEM Model of SCLC and mSCLC Cell Lines
Mice were bred to contain conditional p53 floxed (L) allele (Jonkers et al., 2001)
and Rb floxed (L) allele (Meuwissen et al., 2003) to a final genotype of RP. All
experimental mice were maintained on a mixed genetic background (C57Bl/
6, Balb-c, and S129). From 6 weeks of age, mice were induced with adeno-
virus-Cre recombinase (Ad-Cre) by intratracheal intubation (DuPage et al.,
2009) to allow cre-lox-mediated recombination of floxed p53 and Rb alleles.
Mice were aged 8 to 12 months to allow SCLC disease development. The An-
imal Care and Use Committee of the Dana-Farber Cancer Institute approved
all in vivo experiments performed in this study. mSCLC cell lines were estab-
lished fromRP tumors uponmechanical dissection of tissue. Cells were estab-
lished and maintained in HITES medium (Carney et al., 1981) with 10% fetalFigure 6. Identification of Super-Enhancer-Associated Genes Highly S
(A) Gene set enrichment analysis plot showing significant enrichment of super-e
DMSO-treated cells.
(B) Box plots of log2 fold changes inmean transcript abundance of genes associate
(SEs) upon treatment with 25 or 100 nM THZ1 compared with control (DMSO). W
(C) Heatmap showing the expression of super-enhancer-associated core enrichm
THZ1-treated cells.
(D) Venn diagram showing overlap of ‘‘leading-edge gene’’ (core enriched genes) s
cell line. Gene names in black bold italics are transcription factors, and gene name
transcription factors associated with TOPTEs.
(E) Quantitative PCR to detect expression of indicated gene transcripts in DMSO-t
normalized to GUSB expression, and ‘‘DMSO’’ serves as reference sample set t
(F) Western blotting to detect protein expression of indicated protein in DMSO-tre
control.
See also Table S4 and Figure S6.
920 Cancer Cell 26, 909–922, December 8, 2014 ª2014 Elsevier Inc.bovine serum and cultured at 37C in a humidified chamber with 5% CO2. Ex-
tracted DNA from cell lines was evaluated for p53 and Rb recombination as
previously described (Jonkers et al., 2001; Meuwissen et al., 2003). Cell stocks
were frozen at very low passage (p = 5) for use in screen experiments.
High-Throughput Small-Molecule Screen
Using a semiautomated platform, we tested a >1,000 small-molecule an-
notated library in three mSCLC cell lines (termed mSCLC1, mSCLC2, and
mSCLC3). Cells were seeded in a 384-well format and treated with a concen-
tration of 600 nM of individual compounds before evaluating cell viability after
120 hr (two doubling times) using CellTiter-Glo Lumeniscent assay (Promega).
Further evaluation of compounds that allowed more than 50% inhibition of cell
viability was performed in a five-point 2-fold dilution series of each compound
before evaluating cell viability after 120 hr using CellTiter-Glo (experimental
repeat 1) or MTS-based CKK-8 assay (Dojindo) (experimental repeat 2). See
Supplemental Experimental Procedures.
GEM Dosing Studies and MRI
Mice were imaged using a 7 T BioSpec (Bruker BioSpin) with MRI protocols
optimized for image requisition of pulmonary parenchyma and vessels in
healthy mice. Upon determination of tumor growth, mice were randomized
into treatment groups receiving THZ (Kwiatkowski et al., 2014), Cis-Eto, or
vehicle. See Supplemental Experimental Procedures.
RNA Extraction and Synthetic RNA Spike-In
In short, total RNA from hSCLC cells was prepared using ERCC RNA Spike-In
Mix (Ambion) as previously described (Love´n et al., 2012). See Supplemental
Experimental Procedures.
Microarray Sample Preparation and Analysis
Gene expression analysis on spiked-in RNA sampleswas performed usingHu-
man PrimeView array (Affymetrix) as previously described (Kwiatkowski et al.,
2014). See Supplemental Experimental Procedures.
Chromatin Immunoprecipitation, Sequencing, and Analysis
hSCLC cells were crosslinked and incubated with magnetic bead bound-anti-
body for H3K27Ac (Abcam) before sonication to achieve DNA fragment of 200
to 250 bp. Crosslinks of precipitated protein-DNA complexes were hereafter
reversed, and sequencing was performed using an Illumina HiSeq 2000. See
Supplemental Experimental Procedures.
Additional Procedures
A full description of methods for cellular viability, proliferation, and apoptosis;
3D matrix in vitro assay; western blotting; Bio-THZ1 pull-down, cDNA synthe-
sis, and quantitative PCR; immunohistochemistry; xenograft dosing studies;
gene set enrichment analysis; and functional gene ontology (GO) analysis is
provided in Supplemental Experimental Procedures.
ACCESSION NUMBER
The Gene Expression Omnibus accession number for the microarray and
ChIP-seq data reported in this paper is GSE62614.ensitive to THZ1 in SCLC Cells
nhancer-associated gene signature in 100 nM THZ1-treated cells relative to
dwith the total pool of all enhancers (ALL), TEs, TOPTEs, and super-enhancers
hiskers extend to 1.5 times the interquartile range.
ent genes (leading-edge gene set) identified in (A) in DMSO-treated and 100 nM
ets as identified in (A) and (C) with the top 5%highest expressed genes for each
s in black italics are not transcription factors. Gene names in gray bold italics are
reated and 25 and 100 nM THZ1-treated SCLC cells. Target gene expression is
o ‘‘relative expression’’ index 1. Data are presented as mean ± SEM.
ated and 25 and 100 nM THZ1-treated SCLC cells. ACTIN serves as a loading
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